Cargando…

CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia

Acute myeloid leukemia (AML) relapse is considered to be related to escape from antitumor immunity. Changes in the expression of immune checkpoints, including B7 homolog (H)1 and B7-H2, have been reported to contribute to AML progression. Binding of T cell immunoglobulin and immunoreceptor tyrosine-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaito, Yuta, Hirano, Mitsuhito, Futami, Muneyoshi, Nojima, Masanori, Tamura, Hideto, Tojo, Arinobu, Imai, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721849/ https://www.ncbi.nlm.nih.gov/pubmed/34992684 http://dx.doi.org/10.3892/ol.2021.13169

Ejemplares similares

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
por: Imai, Yoichi, et al.
Publicado: (2019)

Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
por: Hirano, Mitsuhito, et al.
Publicado: (2021)

The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells
por: Futami, Muneyoshi, et al.
Publicado: (2020)

Increased CD112 Expression in Methylcholanthrene-Induced Tumors in CD155-Deficient Mice
por: Nagumo, Yoko, et al.
Publicado: (2014)

Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy
por: Meggyes, Matyas, et al.
Publicado: (2022)

Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma
por: Futami, Muneyoshi, et al.
Publicado: (2017)

Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule
por: Bottino, Cristina, et al.
Publicado: (2003)

CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy
por: Meshitsuka, Sohsuke, et al.
Publicado: (2022)

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia
por: Szereday, Laszlo, et al.
Publicado: (2021)

The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
por: Zeng, Taofei, et al.
Publicado: (2021)

Thiamine Deficiency and Neurological Symptoms in Patients with Hematological Cancer Receiving Chemotherapy: A Retrospective Analysis
por: Iimura, Yohei, et al.
Publicado: (2021)

Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia
por: Safaei, Akbar, et al.
Publicado: (2018)

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia
por: Karnan, Sivasundaram, et al.
Publicado: (2021)

Cytoplasmic DROSHA and Non-canonical Mechanisms of MiR-155 Biogenesis in FLT3-ITD Acute Myeloid Leukemia
por: Nguyen, Le Xuan Truong, et al.
Publicado: (2021)

Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia
por: Wobus, Manja, et al.
Publicado: (2015)

CD112 Regulates Angiogenesis and T Cell Entry into the Spleen
por: Russo, Erica, et al.
Publicado: (2021)

Increased Soluble CD155 in the Serum of Cancer Patients
por: Iguchi-Manaka, Akiko, et al.
Publicado: (2016)

CD155, an onco‐immunologic molecule in human tumors
por: Gao, Jian, et al.
Publicado: (2017)

CD155 and Its Receptors as Targets for Cancer Therapy
por: Paolini, Rossella, et al.
Publicado: (2023)

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
por: Alachkar, Houda, et al.
Publicado: (2013)

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy
por: Jin, Hyung-seung, et al.
Publicado: (2021)

Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody
por: Ma, Wanru, et al.
Publicado: (2019)

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones
por: Al-Mawali, Adhra, et al.
Publicado: (2016)

CD155: A Multi-Functional Molecule in Tumor Progression
por: Molfetta, Rosa, et al.
Publicado: (2020)

Nectin-3 (CD113) Interacts with Nectin-2 (CD112) to Promote Lymphocyte Transendothelial Migration
por: Devilard, Elisabeth, et al.
Publicado: (2013)

Novel MHC-Independent αβTCRs Specific for CD48, CD102, and CD155 Self-Proteins and Their Selection in the Thymus
por: Van Laethem, François, et al.
Publicado: (2020)

FLT3‐ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
por: Soare, Dan‐Sebastian, et al.
Publicado: (2020)

Identification of CD112R as a novel checkpoint for human T cells
por: Zhu, Yuwen, et al.
Publicado: (2016)

Combined Expression of CD34 and FLT3-Internal Tandem Duplication Mutation Predicts Poor Response to Treatment in Acute Myeloid Leukemia
por: Abdellateif, Mona S, et al.
Publicado: (2020)

CD155 contributes to the mesenchymal phenotype of triple‐negative breast cancer
por: Zheng, Qianqian, et al.
Publicado: (2020)

Prognostic value of CD155/TIGIT expression in patients with colorectal cancer
por: Murakami, Daisuke, et al.
Publicado: (2022)

Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis
por: Ohtsuki, Shozo, et al.
Publicado: (2023)

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer
por: Cabioglu, Neslihan, et al.
Publicado: (2023)

Upregulation of the CD155-CD226 Axis Is Associated With Muscle Inflammation and Disease Severity in Idiopathic Inflammatory Myopathies
por: Li, Wenli, et al.
Publicado: (2023)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status
por: Faraoni, Isabella, et al.
Publicado: (2012)

CCDC88C‐FLT3 gene fusion in CD34‐positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia
por: Kurihara, Yuya, et al.
Publicado: (2022)

Relative Expression of BATF and CD112 in PBMC of Patients with Chronic Lymphocytic Leukemia
por: Najafi, Ahmad, et al.
Publicado: (2023)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
por: Okamoto, Yuji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e6mdd4crl09uq56ga4dp9h12mq